CR20120353A - Método de tratamiento de la fibrilación auricular - Google Patents

Método de tratamiento de la fibrilación auricular

Info

Publication number
CR20120353A
CR20120353A CR20120353A CR20120353A CR20120353A CR 20120353 A CR20120353 A CR 20120353A CR 20120353 A CR20120353 A CR 20120353A CR 20120353 A CR20120353 A CR 20120353A CR 20120353 A CR20120353 A CR 20120353A
Authority
CR
Costa Rica
Prior art keywords
treatment
fibrilation
headphone
salts
pharmaceutically acceptable
Prior art date
Application number
CR20120353A
Other languages
English (en)
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120353(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CR20120353A publication Critical patent/CR20120353A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a un método para el tratamiento o la prevención de la fibrilación auricular y/o el aleteo auricular que comprende la coadministración de una cantidad sinérgicamente terapéutica de dronedarona o una sal o sales farmacéuticamente aceptables de la misma y una cantidad sinérgicamente terapéutica de ranolazina o una sal o sales farmacéuticamente aceptables de la misma.
CR20120353A 2009-12-21 2012-06-27 Método de tratamiento de la fibrilación auricular CR20120353A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
PCT/US2010/061257 WO2011084733A1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (1)

Publication Number Publication Date
CR20120353A true CR20120353A (es) 2014-10-07

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120353A CR20120353A (es) 2009-12-21 2012-06-27 Método de tratamiento de la fibrilación auricular

Country Status (37)

Country Link
US (3) US8513254B2 (es)
EP (2) EP2515900B1 (es)
JP (2) JP5723889B2 (es)
KR (2) KR20120107995A (es)
CN (3) CN102665713B (es)
AP (1) AP3536A (es)
AR (1) AR079552A1 (es)
AU (1) AU2010339753B2 (es)
BR (1) BR112012015499A2 (es)
CA (1) CA2784028C (es)
CL (1) CL2012001597A1 (es)
CR (1) CR20120353A (es)
CY (1) CY1116511T1 (es)
DK (1) DK2515900T3 (es)
EA (2) EA025445B1 (es)
EC (1) ECSP12012004A (es)
ES (2) ES2540093T3 (es)
HK (1) HK1170675A1 (es)
HR (1) HRP20150644T1 (es)
HU (1) HUE026916T2 (es)
IL (1) IL220152A (es)
ME (1) ME02179B (es)
MX (2) MX2012007052A (es)
NO (1) NO2749282T3 (es)
NZ (2) NZ627181A (es)
PE (1) PE20121520A1 (es)
PL (2) PL2749282T3 (es)
PT (2) PT2749282T (es)
RS (1) RS54118B1 (es)
SG (3) SG181541A1 (es)
SI (2) SI2515900T1 (es)
SM (1) SMT201500171B (es)
TW (1) TWI508726B (es)
UA (1) UA109887C2 (es)
UY (1) UY33119A (es)
WO (1) WO2011084733A1 (es)
ZA (1) ZA201204608B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4546824B2 (ja) 2002-05-21 2010-09-22 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を処置する方法
AU2010276537B2 (en) 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EP3760180A3 (en) 2009-07-29 2021-01-20 ICU Medical, Inc. Fluid transfer devices and methods of use
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
WO2013112932A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
AU2014296378B2 (en) * 2013-08-02 2017-03-30 Gilead Sciences, Inc. Pharmaceutical compositions of ranolazine and dronedarone
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
US9416128B2 (en) 2013-12-19 2016-08-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
US11865186B2 (en) * 2019-01-24 2024-01-09 Northwestern University Gene therapy treatment of atrial fibrillation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE223218T1 (de) 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
WO2002009761A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DE60117857D1 (de) 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
WO2003009839A1 (en) * 2001-07-20 2003-02-06 Karo Bio Ab Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
JP2008526879A (ja) 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法

Also Published As

Publication number Publication date
CY1116511T1 (el) 2017-03-15
UY33119A (es) 2011-07-29
SG10201710751TA (en) 2018-02-27
TW201136586A (en) 2011-11-01
EP2749282B1 (en) 2017-08-09
PL2515900T3 (pl) 2015-10-30
CN102665713B (zh) 2015-02-18
JP2015057449A (ja) 2015-03-26
IL220152A (en) 2016-11-30
RS54118B1 (en) 2015-12-31
US20140323493A1 (en) 2014-10-30
NZ627181A (en) 2016-02-26
SI2515900T1 (sl) 2015-07-31
CA2784028A1 (en) 2011-07-14
PL2749282T3 (pl) 2018-01-31
ZA201204608B (en) 2013-02-27
WO2011084733A1 (en) 2011-07-14
AU2010339753B2 (en) 2015-01-22
SG181541A1 (en) 2012-07-30
KR20120107995A (ko) 2012-10-04
US8513254B2 (en) 2013-08-20
UA109887C2 (uk) 2015-10-26
EA201290451A1 (ru) 2013-01-30
AR079552A1 (es) 2012-02-01
AP2012006331A0 (en) 2012-06-30
MX2012007052A (es) 2012-07-30
SI2749282T1 (sl) 2017-12-29
AU2010339753A1 (en) 2012-07-12
PE20121520A1 (es) 2012-11-26
JP2013515007A (ja) 2013-05-02
CN104147010A (zh) 2014-11-19
AP3536A (en) 2016-01-13
DK2515900T3 (en) 2015-07-27
EA025445B1 (ru) 2016-12-30
EA201691336A1 (ru) 2017-05-31
US20110183990A1 (en) 2011-07-28
US9056108B2 (en) 2015-06-16
IL220152A0 (en) 2012-07-31
NZ600718A (en) 2014-08-29
HUE026916T2 (en) 2016-08-29
NO2749282T3 (es) 2018-01-06
US20130317038A1 (en) 2013-11-28
ES2646603T3 (es) 2017-12-14
ES2540093T3 (es) 2015-07-08
EP2515900A1 (en) 2012-10-31
ECSP12012004A (es) 2012-08-31
PT2749282T (pt) 2017-11-15
CN104688739A (zh) 2015-06-10
HRP20150644T1 (hr) 2015-07-31
SG10201408528RA (en) 2015-04-29
TWI508726B (zh) 2015-11-21
CL2012001597A1 (es) 2013-06-28
PT2515900E (pt) 2015-07-30
KR20160108611A (ko) 2016-09-19
ME02179B (me) 2015-10-20
EP2749282A1 (en) 2014-07-02
US8754087B2 (en) 2014-06-17
HK1170675A1 (en) 2013-03-08
CA2784028C (en) 2016-08-23
EP2515900B1 (en) 2015-04-29
BR112012015499A2 (pt) 2016-05-03
MX344329B (es) 2016-12-13
CN102665713A (zh) 2012-09-12
SMT201500171B (it) 2015-09-07
JP5723889B2 (ja) 2015-05-27

Similar Documents

Publication Publication Date Title
CR20120353A (es) Método de tratamiento de la fibrilación auricular
NI201500031A (es) Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112016000825A8 (pt) compostos moduladores de sulfonamidas dos canais de sódio, composição farmacêutica, e uso dos mesmos
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112014025122A2 (pt) INIBIDORES DE HISTONA DEACETILASES (HDACs)
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
BR112015012197A2 (pt) terapia de combinação
GT201200038A (es) Composicion para tratar la fibrosis quistica
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
PA8850801A1 (es) Compuestos útiles para inhibir chk1
BR112012032796A2 (pt) miméticos niacina, e os métodos de utilização dos mesmos
BR112015018418A2 (pt) métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112015032534A2 (pt) usos de composto ou de sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, composições farmacêuticas e métodos para prevenir e/ou tratar encefalopatia traumática crônica ou condição relacionada em indivíduo e para tratar indivíduo com lesão de concussão

Legal Events

Date Code Title Description
FC90 Application suspended